Highest-materiality recent filing
Alnylam Q1 net product revs $1.04B (+121%); GAAP EPS $1.51 vs -$0.14; reaffirms FY26 guidance
Global net product revenues $1,036M, up 121% YoY; total TTR revenues $910M (+153%).
Alnylam grants CEO Greenstreet performance-based PSUs tied to $500-$800 stock price by 2029
Target of 55,373 PSUs ($18.0M face value at $325.07 close on grant date).
Alnylam posts Q4 net product rev $995M (+121%); achieves full-year GAAP profitability
Q4 2025 net product revenue $995M (+121% YoY); full-year $2,987M (+81%); total revenue Q4 $1.1B.
Alnylam reports preliminary 2025 net product revs $2,987M (+81% YoY); guides 2026 revs $4.9B-$5.3B
Preliminary 2025 net product revenue $2,987M (81% growth vs 2024); TTR franchise $2,487M (103% growth).
Alnylam Q3 net product rev $851M (+103% YoY); raises 2025 guidance 10% to $2.95-3.05B
Total net product revenues $851M (+103% YoY); TTR franchise $724M (+135% YoY) led by AMVUTTRA ATTR-CM launch.
Issued $661.25M aggregate principal of 0.00% Convertible Senior Notes due 2028; initial conversion price $670.11/share (~40% premium).
Alnylam prices $575M zero-coupon convertible notes due 2028; repurchases $637.8M of 2027 notes
$575M principal of 0.00% convertible senior notes due 2028 priced; initial conversion price ~$670.11/share, 40% premium to VWAP.
Alnylam Q2 net product rev $672M (+64% YoY); TTR franchise $544M (+77%); raises FY guidance
Q2 net product revenues $672M, +64% YoY; TTR franchise $544M (+77%) driven by AMVUTTRA sales of $492M.
Alnylam promotes Pushkal Garg to Chief R&D Officer; merges R&D functions
Pushkal Garg appointed EVP, Chief Research and Development Officer to lead integrated R&D organization.
the Committee approved (i) the appointment of Pushkal Garg, M.D., the Company’s current Chief Medical Officer, Executive Vice President, Development and Medical Affairs, to the position of Executive Vice President, Chief Research and Development Officer
Max materiality 0.85 · Median 0.68 · Most common event earnings